<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="713">
  <stage>Registered</stage>
  <submitdate>14/09/2005</submitdate>
  <approvaldate>29/09/2005</approvaldate>
  <actrnumber>ACTRN12605000559617</actrnumber>
  <trial_identification>
    <studytitle>A double blind randomised, placebo-controlled trial evaluating the effect of Botox injected into the pelvic floor of women with chronic pelvic pain and levator spasm.</studytitle>
    <scientifictitle>To establish the role of botulinum toxin (Botox) injected in the pelvic floor muscles of women with objectively demonstrable pelvic floor spasm, and a history of chronic pelvic pain, as regards to improvement in pain, quality of life and sexual function, compared with placebo.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Chronic pelvic pain and levator spasm.</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Botox injected into the pelvic floor. Twelve weeks intensive follow-up with further follow up at six months following BOTOX injection.</interventions>
    <comparator />
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the effect of Botox injected into the pelvic floor of women compared to placebo using VAS pain assessment</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess the effect of Botox injected into the pelvic floor of women compared to placebo using Bladder and bowel symptoms</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess the effect of Botox injected into the pelvic floor of women compared to placebo using Quality of Life assessments</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess the effect of Botox injected into the pelvic floor of women compared to placebo using Sexual Activity </outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess the effect of Botox injected into the pelvic floor of women compared to placebo using Diary assessments of medication use</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess the effect of Botox injected into the pelvic floor of women compared to placebo using Diary assessments of adverse events</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess the effect of Botox injected into the pelvic floor of women compared to placebo using Physical assessments with Digital vaginal assessment (modified Oxford scale muscle strength measurements)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess the effect of Botox injected into the pelvic floor of women compared to placebo using Physical assessments with manometry and sEMG of the pelvic floor (resting tone pressure, maximum contraction pressure and relaxation pressure)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Economic evaluation of treatments</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome />
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(1)History of chronic pelvic pain for two or more years (2)Documented pelvic floor hypertonicity, with at least two of the following: Muscular myalgia on palpationA pelvic floor resting manometry reading of &gt;40cm waterDysmenorrhea and or dyspareunia that significantly alters quality of lifeWilling to attend the Clinic and comply with the Study requirements for the duration of the Study period i.e., 12 weeks &amp; final follow up at approximately 6 months Age 18 and 55Botox naive (i.e. has not had previous injection of Botox in the pelvic floor).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(1)Current pregnancy (documented by pregnancy test) or a desire for pregnancy during the study period(2)Inability to tolerate vaginal pelvic floor muscle examination and manometry.(3)Significant medical &amp; or psycho-social problems(4)Breast feeding (5)Not willing to use a reliable method of contraception (e.g. barrier methods, the oral contraceptive pill, Depo Provera or other similar depot progestogen or intra- uterine contraceptive device)(6)Poor comprehension of written and spoken English (7)Contraindications for the use of Botox injections. ie: Known hypersensitivity to the formulation of Botox or Xylocaine. (8) Patient currently using aminoglycoside antibiotics(9)History of any neuro-muscular &amp; or bleeding disorder.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Solutions are prepared by a third party not involved in the study and delivered to the examination room without either the patient or the staff attending the study patient aware of the content.</concealment>
    <sequence>Computerised blocks of ten</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>7/01/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allergan Australia Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Allergan Australia Pty Ltd</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To examine the effects of Botox injected into the pelvic floor muscles of women with demonstrable pelvic floor spasm, as regards to pain symptoms, sexual activity, quality of life and economic analysis compared to placebo.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Eastern Area and Illawarra Health Service, Eastern Division</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ms Sherin Jarvis</name>
      <address>Department of Endogynaecology
Royal Hospital for Women
Level 2
Barker Street
Randwick NSW 2031</address>
      <phone>+61 2 93826557</phone>
      <fax>+61 2 93826244</fax>
      <email>jarviss@sesahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Sherin Jarvis</name>
      <address>Department of Endogynaecology
Royal Hospital for Women
Level 2
Barker Street
Randwick NSW 2031</address>
      <phone>+61 2 93826557</phone>
      <fax>+61 2 93826244</fax>
      <email>jarviss@sesahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>